ES2200646B1 - Uso de la cardiotrofina en enfermedades hepaticas. - Google Patents

Uso de la cardiotrofina en enfermedades hepaticas.

Info

Publication number
ES2200646B1
ES2200646B1 ES200102120A ES200102120A ES2200646B1 ES 2200646 B1 ES2200646 B1 ES 2200646B1 ES 200102120 A ES200102120 A ES 200102120A ES 200102120 A ES200102120 A ES 200102120A ES 2200646 B1 ES2200646 B1 ES 2200646B1
Authority
ES
Spain
Prior art keywords
cardiotrophin
hepatic
diseases
liver
role
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200102120A
Other languages
English (en)
Other versions
ES2200646A1 (es
Inventor
Matilde Bustos De Abajo
Jesus Prieto Valtueña
Juan Jose Lasarte Sagastibelza
Elena Baixeras Llano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Medica Aplicada
Original Assignee
Fundacion para la Investigacion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102120A priority Critical patent/ES2200646B1/es
Application filed by Fundacion para la Investigacion Medica Aplicada filed Critical Fundacion para la Investigacion Medica Aplicada
Priority to PCT/ES2002/000445 priority patent/WO2003027146A1/es
Priority to RU2004111977/15A priority patent/RU2279289C2/ru
Priority to AT02772422T priority patent/ATE416194T1/de
Priority to SI200230788T priority patent/SI1437365T1/sl
Priority to BR0212903-5A priority patent/BR0212903A/pt
Priority to ES02772422T priority patent/ES2316616T3/es
Priority to MXPA04002672A priority patent/MXPA04002672A/es
Priority to DK02772422T priority patent/DK1437365T3/da
Priority to CNB028185331A priority patent/CN1243020C/zh
Priority to PT02772422T priority patent/PT1437365E/pt
Priority to AU2002337196A priority patent/AU2002337196B2/en
Priority to JP2003530732A priority patent/JP4290004B2/ja
Priority to CA2461007A priority patent/CA2461007C/en
Priority to EP02772422A priority patent/EP1437365B1/en
Priority to DE60230172T priority patent/DE60230172D1/de
Publication of ES2200646A1 publication Critical patent/ES2200646A1/es
Priority to US10/798,219 priority patent/US7732397B2/en
Application granted granted Critical
Publication of ES2200646B1 publication Critical patent/ES2200646B1/es
Priority to CY20091100209T priority patent/CY1109800T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso de la cardiotrofina en enfermedades hepáticas.
La invención describe la expresión aumentada de cardiotrofina (CT-1) durante el proceso de regeneración hepática en coincidencia con la máxima proliferación de hepatocitos y también el papel de CT-1 como estimulador de la regeneración hepática. Asimismo se describe el papel hepatoprotector de CT-1 en distintos modelos de daño agudo hepático.
Todo ello pone de manifiesto la importancia del uso de CT-1 en la fabricación de composiciones útiles en el tratamiento de hepatopatías. En la invención se describe esta utilización bajo diferentes formas y procedimientos, incluyendo la proteína recombinante y la utilización de las secuencias génicas que codifican para CT-1.
ES200102120A 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas. Expired - Fee Related ES2200646B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES200102120A ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.
AU2002337196A AU2002337196B2 (en) 2001-09-21 2002-09-20 Use of cardiotrophin in hepatic diseases
AT02772422T ATE416194T1 (de) 2001-09-21 2002-09-20 Verwendung von cardiotrophin bei leberkrankheiten
SI200230788T SI1437365T1 (sl) 2001-09-21 2002-09-20 Uporaba kardiotrofina pri boleznih jeter
BR0212903-5A BR0212903A (pt) 2001-09-21 2002-09-20 Uso de cardiotrofina em doenças do fìgado
ES02772422T ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.
MXPA04002672A MXPA04002672A (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.
DK02772422T DK1437365T3 (da) 2001-09-21 2002-09-20 Anvendelse af cardiotrophin ved hepatiske sygdomme
CNB028185331A CN1243020C (zh) 2001-09-21 2002-09-20 促心激素在肝病中的应用
CA2461007A CA2461007C (en) 2001-09-21 2002-09-20 Use of cardiotrophin in liver diseases
PCT/ES2002/000445 WO2003027146A1 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas
RU2004111977/15A RU2279289C2 (ru) 2001-09-21 2002-09-20 Применение кардиотрофина при заболеваниях печени
PT02772422T PT1437365E (pt) 2001-09-21 2002-09-20 Utilização de cardiotrofina em doenças hepáticas
EP02772422A EP1437365B1 (en) 2001-09-21 2002-09-20 Use of cardiotrophin in hepatic diseases
DE60230172T DE60230172D1 (de) 2001-09-21 2002-09-20 Verwendung von cardiotrophin bei leberkrankheiten
JP2003530732A JP4290004B2 (ja) 2001-09-21 2002-09-20 肝臓疾患におけるカルジオトロフィンの使用
US10/798,219 US7732397B2 (en) 2001-09-21 2004-03-11 Use of cardiotrophin in liver diseases
CY20091100209T CY1109800T1 (el) 2001-09-21 2009-02-25 Χρηση καρδιοτροφινης σε ηπατικες ασθενειες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102120A ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.

Publications (2)

Publication Number Publication Date
ES2200646A1 ES2200646A1 (es) 2004-03-01
ES2200646B1 true ES2200646B1 (es) 2005-05-01

Family

ID=8498979

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200102120A Expired - Fee Related ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.
ES02772422T Expired - Lifetime ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02772422T Expired - Lifetime ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.

Country Status (17)

Country Link
US (1) US7732397B2 (es)
EP (1) EP1437365B1 (es)
JP (1) JP4290004B2 (es)
CN (1) CN1243020C (es)
AT (1) ATE416194T1 (es)
AU (1) AU2002337196B2 (es)
BR (1) BR0212903A (es)
CA (1) CA2461007C (es)
CY (1) CY1109800T1 (es)
DE (1) DE60230172D1 (es)
DK (1) DK1437365T3 (es)
ES (2) ES2200646B1 (es)
MX (1) MXPA04002672A (es)
PT (1) PT1437365E (es)
RU (1) RU2279289C2 (es)
SI (1) SI1437365T1 (es)
WO (1) WO2003027146A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249340B2 (en) * 2003-06-25 2011-04-21 Ottawa Hospital Research Institute Use of cardiotrophin to modulate stem cell proliferation
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP2578082A2 (en) * 2010-05-24 2013-04-10 Digna Biotech, S.L. Composition for the cold storage of organs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755446B1 (en) 1994-04-25 2006-09-13 Genentech, Inc. Cardiotrophin and uses therefor
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
CA2295326A1 (en) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
ATE295963T1 (de) * 1999-01-21 2005-06-15 Genentech Inc Zusammensetzungen sowie verfahren zur diagnose und behandlung von tumorerkrankungen
US6719969B1 (en) * 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
CA2447116A1 (en) * 2001-05-17 2002-11-21 Board Of Trustees Of The University Of Illinois Methods for treating liver disease and liver damage with growth hormone and foxm1b

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONGKUI, J. et al. "In vivo effects of cardiotrophin-1". CYTOKINE, Vol. 8, nº 12, 1996, páginas 920-926, todo el documento. *
PETERS, M. et al. "A new hepatocyte stimulating factor: Cardiotrophin-1 (CT-1)". FEBS LETTERS, Vol. 372, nº 2-3, 1995, páginas 177-180, todo el documento. *
RICHARDS, C.D. et al. "Murine Cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells". JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, Vol. 16, nº 1, 1996, páginas 69-75, todo el documento. *
ROBLEDO, O. et al. "Hepatocyte-derived cell lines express a functional receptor of cardiotrophin-1". EUROPEAN CYTOKINE NETWORK, Vol. 8, nº 3, 1997, páginas 245-252, todo el documento. *

Also Published As

Publication number Publication date
DE60230172D1 (de) 2009-01-15
US7732397B2 (en) 2010-06-08
CN1243020C (zh) 2006-02-22
EP1437365B1 (en) 2008-12-03
CA2461007C (en) 2014-02-11
BR0212903A (pt) 2004-09-14
US20040224888A1 (en) 2004-11-11
DK1437365T3 (da) 2009-03-23
JP2005512966A (ja) 2005-05-12
CN1556816A (zh) 2004-12-22
ES2316616T3 (es) 2009-04-16
MXPA04002672A (es) 2004-11-22
ATE416194T1 (de) 2008-12-15
CY1109800T1 (el) 2014-09-10
RU2279289C2 (ru) 2006-07-10
PT1437365E (pt) 2009-03-10
AU2002337196B2 (en) 2008-03-13
RU2004111977A (ru) 2005-04-10
SI1437365T1 (sl) 2009-06-30
JP4290004B2 (ja) 2009-07-01
CA2461007A1 (en) 2003-04-03
WO2003027146A1 (es) 2003-04-03
ES2200646A1 (es) 2004-03-01
EP1437365A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
DOP2020000071A (es) Proteínas trispecificas y métodos de uso
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
MX2024006240A (es) Vacunas contra el metapneumovirus humano.
DK1680507T3 (da) Bakterieekspression af proteaseinhibitorer og varianter deraf
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
ATE312096T1 (de) Neue verbindungen
MX2022014161A (es) Vacunas contra sars-cov-2.
MX2017010259A (es) Proteina resistente a herbicidas, gen codificante y uso de los mismos.
HRP20050024A2 (en) Pegylated t20 polypeptide
ATE461453T1 (de) Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt
DE50310323D1 (de) Wässrige polyurethanzubereitungen
DK1075523T3 (da) Strukturelle proteiner hos fiskepankreassygdomsvirus og anvendelser deraf
ES2200646A1 (es) Uso de la cardiotrofina en enfermedades hepaticas.
ATE482976T1 (de) Defensinproteine
ATE520776T1 (de) Rekombinantes herpesvirus und dessen nutzung
ATE391489T1 (de) Haarbehandlungszusammensetzungen
DE602004006363D1 (de) Verfahren zur Herstellung von Polyarylenpolyethern mit Aminoendgruppen
DOP2006000117A (es) Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada

Legal Events

Date Code Title Description
PC2A Transfer of patent
EC2A Search report published

Date of ref document: 20040301

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2200646B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20190521

FD2A Announcement of lapse in spain

Effective date: 20190604